The Ministry of Health approved five Productive Development Partnerships (PDP), between the future Butantan Farma and private companies, for the production of antiretrovirals, oncology medicines and for the treatment of rare diseases. The medicines will be destined for the Unified Health System (SUS).
Butantan Farma is the new name of the Foundation for Popular Medicine Chopin Tavares de Lima (Furp), an organization linked to the São Paulo State Department of Health (SES-SP). On November 11, the Legislative Assembly of the State of São Paulo (Alesp) approved the bill for the Butantan Institute to incorporate Furp.
The announcement was made during a plenary meeting of the Executive Group of the Health Economic-Industrial Complex, held this Monday (24), with the presence of the Minister of Health, Alexandre Padilha. Also present were the director of the Butantan Institute, Esper Kallás; the director of the Butantan Foundation, Saulo Nacif; the superintendent of FURP, Rogério Aunda; and the acting Secretary of State for Health, Priscilla Perdicaris.
Partnerships are being made with private companies Cristália, Prati & Donaduzzi, Biocon Pharma and Nortec, Blanver and Cyg Biotech, which will allow the expansion of the production of medicines for the treatment of rare diseases, such as cystic fibrosis and amyloidosis; oncological diseases, such as leukemia and renal cell carcinoma; and neglected diseases, such as antiretroviral (HIV).
At the event, the Ministry of Health also announced an investment of R$15 billion in the industrial sector and closed a total of 31 new Productive Development Partnerships (PDP) to expand the national production of strategic products for the SUS and the supply of medicines and vaccines to the population.
The selection of new PDP projects, which involves public and private institutions for the transfer of technology to the country, has not occurred since 2017, being resumed by the current government with the record receipt of 147 new projects in the public call.
Approved partnerships
- Ivacaftor 150mg: coated tablet presentation, indicated for cystic fibrosis, which will be developed in partnership with Cristália, with production scheduled after the end of patent protection, which expires in June 2026;
- Tafamidis Meglumina 20mg: soft capsule presentation, indicated for Amyloidosis, in partnership with Prati & Donaduzzi, no longer patent protected;
- Dasatinib 20 and 100mg: tablet presentation, indicated for Leukemia Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML), partnership with Biocon Pharma and Nortec, no longer patent protected;
- Pazopanib 200mg and 400mg: coated tablet presentation, for the treatment of renal cell carcinoma, developed in partnership with Blanver and Cyg Biotech, without patent protection;
- Dolutegravir 50mg + Lamivudine 300mg: antiretroviral tablet for HIV treatment, in partnership with Blanver and Cyg Biotech, with production scheduled after the end of patent protection, which expires in April 2026.
